DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie

References

Gadgeeel SM. et al.
OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses.

WCLC; 2016 abstr. PL04a.02

Download Bibliographical Data

Access: